Menu

Former NIH Director James Wyngaarden Dies

The Duke University emeritus professor was an expert in purine biosynthesis and the genetics of gout.

Jun 20, 2019
Jef Akst
OFFICE OF NIH HISTORY AND STETTEN MUSEUM, NATIONAL INSTITUTES OF HEALTH

Former Duke University researcher and administrator James Wyngaarden, who directed the National Institutes of Health from 1982 to 1989, died last week (June 14) at age 94.

“Jim Wyngaarden was a giant among the greatest generation of leaders of American medicine of the 20th Century,” Ralph Snyderman, chancellor emeritus of health affairs at Duke University, says in a statement. “Jim was a creator and model of the physician-scientist, and he had an extraordinary ability to recruit the best people to Duke.”

As chair of the Department of Medicine from the late ’60s until he left to run the NIH in 1982, Wyngaarden recruited, trained, or mentored some three dozen doctors who went on to become medical department chairs, deans, or health system executives themselves, according to the release. After his stint as NIH director, he returned to Duke as associate vice chancellor for health affairs.

Wyngaarden was a world-renowned expert in purine synthesis as well as in the genetics of gout, a complex form of arthritis. Wyngaarden and colleagues discovered that hyperuricemia (too much uric acid in the blood) is a precursor of gout, and that revelation led to the development of a treatment for the condition.

In a letter mourning Wyngaarden’s passing, current NIH Director Francis Collins spoke of his “masterful leadership” during his seven-year run at the agency. “While at the helm of NIH, Dr. Wyngaarden steered the nation’s biomedical research agency through uncharted seas with extraordinary skill,” Collins writes, noting Wyngaarden’s roles in the country’s early research into HIV/AIDS and in the international Human Genome Project. “I am grateful for Dr. Wyngaarden’s selfless dedication to NIH’s mission of turning scientific discovery into health. Whether researcher, health care provider, or patient, we are all benefiting from his wisdom to this day, and will remain forever in his debt.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.